Life sciences company focused on progressing psychedelics therapeutics by utilizing proprietary drug discovery platforms and unique delivery mechanisms Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has filed for two additional international patent applications related to its research phase programs.
The international patent application gives patent coverage in 153 countries around the world for any single patent. These patents are normally under the Patent Cooperation Treaty (PCT). The PCT gives the company rights to file national applications into treaty member state in the future.
One of the patent applications says a group of proprietary compounds captured by the Cybin’s research data as being very vital for future evaluation in the selection of potential therapeutics.
The second patent application, includes claims and disclosures related to other multiple proprietary novel psychedelics compounds inclusive of compounds with positive research data which meet the internal research criteria of Cybin.
Cybin says these applications will add synergies to its CYB005 program which is aimed at therapy resistant psychiatric disorders and to provide compositions for further evaluation in future research activities.
